Edition:
India

BiondVax Pharmaceuticals Ltd (BVXV.OQ)

BVXV.OQ on NASDAQ Stock Exchange Capital Market

6.07USD
17 Jan 2018
Change (% chg)

$0.19 (+3.14%)
Prev Close
$5.89
Open
$5.94
Day's High
$6.07
Day's Low
$5.94
Volume
507
Avg. Vol
7,105
52-wk High
$10.75
52-wk Low
$4.20

Chart for

About

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a... (more)

Overall

No Ratios Available.

Financials

BRIEF-Biondvax Universal Flu Vaccine Patent Granted In India

* BIONDVAX UNIVERSAL FLU VACCINE PATENT GRANTED IN INDIA Source text for Eikon: Further company coverage:

02 Jan 2018

BRIEF-Biondvax Plans Phase 3 Clinical Trial Following Receipt Of Scientific Advice From The European Medicines Agency

* BIONDVAX PLANS PHASE 3 CLINICAL TRIAL FOLLOWING RECEIPT OF SCIENTIFIC ADVICE FROM THE EUROPEAN MEDICINES AGENCY (EMA)

27 Dec 2017

BRIEF-Biondvax Pharmaceuticals Ltd Reports Qtrly Loss Per Share of NIS 0.01 ‍​

* BIONDVAX PHARMACEUTICALS LTD - QTRLY LOSS PER SHARE NIS 0.01 ‍​ Source text for Eikon: Further company coverage:

28 Nov 2017

BRIEF-BiondVax and NIH sign clinical trial agreement for phase 2 trial for universal flu vaccine

* BiondVax and NIH sign clinical trial agreement for a phase 2 trial in the U.S. with BiondVax's universal flu vaccine

20 Nov 2017

BRIEF-Eastern Capital reports 7.3 pct passive stake in Biondvax Pharmaceuticals

* Eastern capital ltd reports 7.3 percent passive stake in Biondvax Pharmaceuticals Ltd as of September 18, 2017 - SEC Filing Source text: (http://bit.ly/2wSBhH6) Further company coverage:

27 Sep 2017

BRIEF-Ibex Investors reports 5.5 pct passive stake in BiondVax Pharma

* Ibex Investors LLC reports 5.5 percent passive stake in BiondVax Pharmaceuticals Ltd as of Sept 14, 2017 - SEC filing Source text: (http://bit.ly/2fGw3nu) Further company coverage:

23 Sep 2017

BRIEF-BiondVax announces pricing of public offering of American Depositary Shares

* BiondVax announces pricing of public offering of American Depositary Shares

14 Sep 2017

BRIEF-BiondVax announces public offering of American Depositary Shares

* BiondVax announces public offering of American Depositary Shares

14 Sep 2017

BRIEF-BiondVax Pharmaceuticals reports qtrly loss per share of NIS 0.07

* Qtrly loss per share NIS 0.07 Source text for Eikon: Further company coverage:

31 Aug 2017

BRIEF-Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

* Dual-listed BiondVax to voluntarily delist from Tel Aviv Stock Exchange

31 Aug 2017

Earnings vs. Estimates